SEC 13F Intelligence

Managers / Q1 2021 · view latest →

Bain Capital Life Sciences Investors, LLC

CIK 0001703031 · 200 CLARENDON STREET, BOSTON, MA, 02116 · 6175162878

Reported Value
$1.8B
Q1 2021
Positions
31
Filings on Record
30
2019–present window
Filed
May 17, 2021
original filing

Summary

Bain Capital Life Sciences Investors, Llc reported $1.8B in U.S.-listed holdings across 31 positions for Q1 2021.

The portfolio is heavily concentrated: SWTXUSD alone accounts for 24.3% of reported value.

Compared with Q4 2020, the fund opened 7 new positions and exited 2.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $293MQ4 ’18Q1 ’19: $250MQ2 ’19: $197MQ3 ’19: $388MQ4 ’19: $671MQ4 ’19Q1 ’20: $591MQ2 ’20: $955MQ3 ’20: $1.1BQ4 ’20: $1.6BQ4 ’20Q1 ’21: $1.8BQ2 ’21: $1.5BQ3 ’21: $1.6BQ4 ’21: $1.3BQ4 ’21Q1 ’22: $1.0BQ2 ’22: $853MQ3 ’22: $838MQ4 ’22: $895MQ4 ’22Q1 ’23: $800,117Q2 ’23: $971MQ3 ’23: $894MQ4 ’23: $1.0BQ4 ’23Q1 ’24: $1.2BQ2 ’24: $911MQ3 ’24: $961MQ4 ’24: $850MQ4 ’24Q1 ’25: $676MQ2 ’25: $799MQ3 ’25: $1.5BQ4 ’25: $1.3BQ4 ’25Q1 ’26: $1.1Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 83.0%Other: 17.0%
  • Common Stock · 83.0% · $1.5B
  • Other · 17.0% · $301M

Quarter-over-Quarter Changes full breakdown →

Holdings — Q1 2021

Loading…
Export to Excel
#IssuerClass% PortfolioValue ↓Shares

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.1B20May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.3B19Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.5B21Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$799M23Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$676M24May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$850M26Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$961M24Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$911M25Aug 12, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.2B26May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.0B27Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$894M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$971M32Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$800,11734May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$895M33Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$838M33Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$853M35Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.0B34May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.3B34Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.6B33Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.5B30Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.8B31May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.6B26Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.1B22Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$955M15Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$591M11May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$671M10Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$388M7Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$197M5Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$250M6May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$293M6Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 5 additional managers.

  • Bain Capital Life Sciences Partners, LP28-18476
  • Bain Capital Life Sciences Fund, L.P.28-18478
  • BC SW, LP28-20270
  • Bain Capital Life Sciences Investors II, LLC28-20816
  • Bain Capital Life Sciences Fund II, L.P.28-20814

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.